Why Eli Lilly Is Underrated in the Red-Hot GLP-1 Weight-Loss Drug Race, per Morgan Stanley May 25, 2026 Life Science
Strong Performance in Healthcare Sector Driven by Multiple Positive Factors May 22, 2026 Life Science
Three Recession-Resistant Stocks Worth Investors’ Attention May 22, 2026 Consumer Goods, Life Science
The Market Underestimates Bristol-Myers Squibb’s New Product Growth Potential May 21, 2026 Life Science
Can Viking Therapeutics Replicate Eli Lilly’s Success in the Weight-Loss Drug Market? May 21, 2026 Life Science
With the Macroeconomic Environment Improving, these Three Biotech Stocks Are Worth Watching May 21, 2026 Life Science
These Two Healthcare Giants Set for Fresh Dividend Hikes, Ideal Time to Invest May 19, 2026 Life Science
Bullish on Oncology Drug Potential? This Biotech Fund Increases Stake in Enliven Therapeutics May 13, 2026 Life Science
Hantavirus Fears Fuel Moderna Rally: Is This a Real Catalyst or Just Sentiment? May 11, 2026 Life Science
Eli Lilly Stock Hits Bottleneck After 400% Surge in Five Years, Novo Nordisk Poised for a Comeback with 4% Dividend Yield May 8, 2026 Life Science
As Summer Approaches, These TSX Stocks May Be Worth Positioning in Advance May 8, 2026 Mining, Precious Metals
Quarterly Sales Reach $8.7 Billion, Eli Lilly’s Mounjaro Becomes New Blockbuster Drug King May 6, 2026 Life Science
